Table 4 PAH therapy at the time of final visit in the study at Chiba University Hospital (PoPH and I/H-PAH)
From: The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan
PoPH | I/H-PAH | p value | |
|---|---|---|---|
Modern PAH therapy (±) (%) | 7/4 [64] | 33/6 [85] | 0.1442 |
IV PGI2 (±) (%) | 0/11 [0] | 10/29 [26] | 0.0176 |
ERA (±) (%) | 5/6 [45] | 22/17 [56] | 0.5202 |
PDE5i (±) (%) | 4/7 [36] | 28/11 [72] | 0.0335 |
PGI2 receptor agonist (±) (%) | 1/10 [1] | 11/28 [28] | 0.1567 |
Combination therapy (±) (%) | 3/8 [27] | 26/13 [67] | 0.0191 |